RecruitingNon-Small Cell Lung CancerNSCLCEGFR/HER2 Exon 20 Insertion Mutation
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
Eligible age
18+ yrs
Accepts
All genders
Locations
7 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Study STX-721-101/PFL-721CI101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721/PFL-721 in participants with non-small cell lung cancer (NSCLC) carrying EGFR or HER2 exon 20 insertion (ex20ins) mutations.
Sponsor: Pierre Fabre Medicament
Where it's recruiting
California
Duarte · Huntington Beach · Irvine
North Carolina
Charlotte
Pennsylvania
Philadelphia
Tennessee
Nashville
Texas
Houston
Utah
Salt Lake City
Virginia
Fairfax
Source: ClinicalTrials.gov · NCT06043817 · last updated 2026-05-22